oricar-017
oricell therapeutics
['mmsm']
in this phase i study, oricar-017 was showed safe and impressive efficacy in rrmm patients. majority of aes were transient and manageable. 100% orr and 100% mrd negative rate, along with favorable safety support oricar-017 to be a competitive therapy for rrmm #mmsm #asco22 
Multiple Myeloma Education Platform for Myeloma Community